Drugs / MT1013
last change Dec 2025 re-read 2 minutes ago

MT1013

Peptide

Developed for
secondary hyperparathyroidism of renal origin
Investigated by
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · WCCT Global

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07284043 Nov 2025 → Nov 2026 expected secondary hyperparathyroidism of renal origin Shaanxi Micot Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT04783090 Jun → Dec 2021 Shaanxi Micot Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06690242 Nov 2024 → Oct 2025 secondary hyperparathyroidism of renal origin Shaanxi Micot Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 2 NCT06976177 Jun 2024 → Aug 2025 overdue secondary hyperparathyroidism of renal origin Shaanxi Micot Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06747247 Apr 2023 → May 2025 secondary hyperparathyroidism of renal origin Shaanxi Micot Pharmaceutical Technology Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT07122401 Sep 2025 → Nov 2026 expected secondary hyperparathyroidism of renal origin Shaanxi Micot Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as MT1013 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06690242
5

NCT07122401

NCT07284043

NCT04783090

NCT06747247

NCT06976177

Action Activate “CaSR agonist” NCT04783090
Modality Peptide “bispecific peptide as a CaSR agonist and a functional OGP analogue” NCT04783090
Route Intravenous “MT1013 injection dose regimen 1 administered intravenously (IV) three times per week for 26 weeks.” NCT06690242